-
公开(公告)号：US11911357B2
公开(公告)日：2024-02-27
申请号：US17332194
申请日：2021-05-27
Applicant: Alcresta Therapeutics, Inc.
Inventor： Robert Gallotto , Greta L. Loring , Kenneth Gary , Edward S. Park , David J. Brown , Willem Robert Klaas Schoevaart , Michiel Christian Alexander van Vliet
IPC: A23L33/00 , C12N9/20 , A61K31/202 , A61L29/04 , A61M5/14 , A61M5/142 , C12N11/06 , A61J15/00 , A23L33/12 , C12N11/087 , C12N11/089
CPC classification number: A61K31/202 , A23L33/00 , A23L33/12 , A23L33/40 , A61J15/0076 , A61L29/048 , A61M5/14 , A61M5/142 , A61M5/1413 , C12N9/20 , C12N11/06 , C12N11/087 , C12N11/089
Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.
-
62.发明公开
公开(公告)号：US20240058293A1
公开(公告)日：2024-02-22
申请号：US18382446
申请日：2023-10-20
Applicant: Emory University , Children's Healthcare of Atlanta, Inc.
Inventor： Claudia R. Morris
IPC: A61K31/23 , A61K31/202 , A61K31/122 , A61K31/07 , A61K31/59 , A61K38/46 , A61K31/7004 , A61K31/473 , A61K35/741 , A61K33/26 , A61K31/661 , A61K33/18 , A61K33/34 , A61K33/32 , A61K33/24 , A61K31/047 , A61K31/385 , A61K31/205 , A61K31/375 , A61K33/30 , A61K31/355 , A23L33/175 , A23L33/15 , A23L33/12 , A61K31/22 , A61K33/42 , A23L33/00 , A61K45/06 , A23L33/16 , A61K31/19 , A61K31/4375 , A23L33/155 , A61K31/231 , A61K9/00 , A61K31/232 , A61K31/20 , A23L33/135
CPC classification number: A61K31/23 , A61K31/202 , A61K31/122 , A61K31/07 , A61K31/59 , A61K38/46 , A61K31/7004 , A61K31/473 , A61K35/741 , A61K33/26 , A61K31/661 , A61K33/18 , A61K33/34 , A61K33/32 , A61K33/24 , A61K31/047 , A61K31/385 , A61K31/205 , A61K31/375 , A61K33/30 , A61K31/355 , A23L33/175 , A23L33/15 , A23L33/12 , A61K31/22 , A61K33/42 , A23L33/40 , A61K45/06 , A23L33/16 , A61K31/19 , A61K31/4375 , A23L33/155 , A61K31/231 , A61K9/0056 , A61K31/232 , A61K31/20 , A23L33/135 , A23V2002/00 , A61K2035/115
Abstract: Disclosed are nutritional formulations and uses for treating or preventing a gastrointestinal condition and/or motor-planning speech and/or coordination difficulties. In certain embodiments, the nutritional formulations comprise medium chain fatty acids, or esters thereof (such as and tri-, di-, mono-glycerides, or alkyl esters), unsaturated fatty acids, and a vitamin E and optionally other nutrients. In certain embodiments, any of the compounds or nutrients may be in alternative salt forms.
-
公开(公告)号：US20240057626A1
公开(公告)日：2024-02-22
申请号：US18259286
申请日：2021-12-31
Applicant: N.V. Nutricia
Inventor： Cameron Marshall , Tuan Nguyen , Ana Ospina Martinez
IPC: A23C9/144 , A23C9/142 , A23L33/00 , A23L33/125 , B01D61/14 , B01D61/02 , B01D61/58 , B01D69/02 , B01D61/42 , A61K31/7016 , C13K5/00
CPC classification number: A23C9/144 , A23C9/1422 , A23L33/40 , A23L33/125 , B01D61/145 , B01D61/027 , B01D61/58 , B01D69/02 , B01D61/422 , A61K31/7016 , C13K5/00 , A23C2210/202 , A23C2210/206 , B01D2311/06 , B01D2325/20 , B01D2311/08
Abstract: The present invention provides a process of producing a lactose concentrate, said process comprising the step of subjecting a partially demineralised aqueous lactose isolate to electrodialysis to produce a biotin-reduced lactose isolate containing at least 90% lactose by weight of dry matter and less than 2 mg ash per gram of lactose, and containing:
0.02-1.5 mg sodium per gram of lactose;
0.02-2 mg potassium per gram of lactose;
0.05-1.5 mg chloride per gram of lactose;
0.01-0.25 μg biotin per gram of lactose.
The present invention also relates to a demineralised lactose concentrate having a reduced biotin content that can be produced by the aforementioned process. The invention further relates to an oligosaccharide-enriched biotin-reduced fraction that is obtained when lactose is separated before or after the electrodialysis step.
-
64.发明授权
公开(公告)号：US11896610B2
公开(公告)日：2024-02-13
申请号：US17870026
申请日：2022-07-21
Applicant: Vector Vitale IP LLC
Inventor： Peter Y. Novak , Maxim V. Temnikov
IPC: A01G31/00 , A61K33/30 , A61K36/42 , A61K36/73 , A61K33/06 , A61K33/26 , A61K33/00 , A61K35/57 , A61K35/12 , A61K31/315 , A61K35/60 , C05G5/23 , C05D9/02 , A01C21/00 , A23K20/20 , A23K20/142 , A23K50/30 , A23K50/75 , A23K50/80 , A23L33/00 , A23L33/16 , A23L33/175 , A23L13/50 , A23L13/40 , A23L17/00 , A23L15/00 , A61K36/81
CPC classification number: A61K33/30 , A01C21/007 , A01G31/00 , A23K20/142 , A23K20/30 , A23K50/30 , A23K50/75 , A23K50/80 , A23L13/428 , A23L13/432 , A23L13/55 , A23L15/30 , A23L17/00 , A23L33/16 , A23L33/175 , A23L33/40 , A61K31/315 , A61K33/00 , A61K33/06 , A61K33/26 , A61K35/12 , A61K35/57 , A61K35/60 , A61K36/42 , A61K36/73 , A61K36/81 , C05D9/02 , C05G5/23 , A23V2002/00
Abstract: Engineered food to promote health and maintain homeostasis in a subject and methods of producing the food.
-
公开(公告)号：US20240041968A1
公开(公告)日：2024-02-08
申请号：US18486306
申请日：2023-10-13
Applicant: GOLO LLC
Inventor： Christopher Brian LUNDIN , Terry Shirvani
IPC: A61K36/73 , A61K36/41 , A23L33/00 , A61K33/06 , A61P3/00 , A61K33/30 , A61K36/37 , A61K36/185 , A61K36/744
CPC classification number: A61K36/73 , A61K36/41 , A23L33/30 , A61K33/06 , A61P3/00 , A61K33/30 , A61K36/37 , A61K36/185 , A61K36/744
Abstract: A weight loss composition including banaba leaf extract, apple fruit extract, Rhodiola root extract, zinc chelate, and magnesium chelate are described. The weight loss composition may further include gardenia fruit extract, chromium chelate, Salacia extract, berberine, inositol, or mixtures thereof. Embodiments are also directed to a bulk food product and a weight management plan, which may be used in conjunction with the weight loss composition. Embodiments are also directed to kits and methods of use for treating or preventing obesity, promoting weight loss, and improving insulin resistance.
-
公开(公告)号：US20240041826A1
公开(公告)日：2024-02-08
申请号：US17818026
申请日：2022-08-08
Applicant: Rory Powell Blake
Inventor： Rory Powell Blake
IPC: A61K31/401 , A61K31/198 , A23L33/175 , A23L2/52 , C12G3/04 , A23D9/007 , A23L33/00
CPC classification number: A61K31/401 , A61K31/198 , A23L33/175 , A23L2/52 , C12G3/04 , A23D9/007 , A23L33/40 , A23V2002/00
Abstract: The human body's response to excessive gut bacterial growth is to deny the microbiome of two classes of amino acids. This halts exponential growth; however, the body is also denied their benefit. In the short term, prevention of explosive infection is accomplished. However, this triggers the necessity of removing the needed amino acids from bodily structure for the body to continue. This becomes the resulting long-term decline seen in human aging. This disclosure is methods to extend to the body the benefit of those missing classes of amino acids by providing them in a form less accessible to bacteria. The preferred embodiments claimed in this disclosure work in tandem to treat and to slow aging.
-
公开(公告)号：US11890317B2
公开(公告)日：2024-02-06
申请号：US17856729
申请日：2022-07-01
Applicant: NovMetaPharma Co., Ltd.
Inventor： Hoe-Yune Jung , Heon-Jong Lee , Jong-Su Jeon , Yon-Su Kim , Seung-Hee Yang , Yong-Chul Kim , Jong-Joo Moon , Hwan-Soo Yoo , Kyeong-Mi Choi
CPC classification number: A61K38/12 , A23L33/00 , A23L33/18 , A61K38/05 , A61P31/00 , A61P35/00 , C07K5/12 , A23V2002/00 , A23V2200/308 , A23V2250/55 , A61P1/16 , A61K38/12 , A61K2300/00
Abstract: A new use of a cyclo histidine-proline (Cyclo His-Pro, CHP) is disclosed. A composition including cyclo histidine-proline (CHP) as an active ingredient has an excellent protective effect to protect kidney and liver cells from damage and/or toxicity induced by various causes. The composition is useful and effective in protecting kidney and/or liver cells/tissues and in treating a subject with kidney and/or liver diseases and/or damages.
-
公开(公告)号：US20240032581A1
公开(公告)日：2024-02-01
申请号：US18257330
申请日：2021-12-17
Applicant: SOCIETE DES PRODUITS NESTLE S.A.
Inventor： ARISTEA BINIA , IRENE VASSALLO
IPC: A23L33/125 , A23L33/00 , A61K31/702 , A61P3/02
CPC classification number: A23L33/125 , A23L33/40 , A61K31/702 , A61P3/02
Abstract: Synthetic nutritional compositions tailored for Chinese infants comprising 3′-SL and 6′-SL in concentrations reflecting those found in human milk produced for infants from the same regional location.
-
公开(公告)号：US11883441B2
公开(公告)日：2024-01-30
申请号：US17486299
申请日：2021-09-27
Applicant: The Regents of the University of California
Inventor： Elaine Y. Hsiao , Jessica Yano , Helen E. Vuong , Christine Olson
IPC: A61K35/741 , A61K39/02 , A61K35/00 , A61K35/74 , A61K9/00 , A23L33/135 , A23L33/00 , A61P25/00
CPC classification number: A61K35/74 , A23L33/135 , A23L33/30 , A61K35/741 , A61K39/0216 , A61P25/00 , A61K9/0031 , A61K9/0053 , A61K2035/115
Abstract: Provided herein are methods and compositions related to treating or preventing seizures. In some aspects, provided herein are methods of treating or preventing seizures in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.
-
公开(公告)号：US20240006051A1
公开(公告)日：2024-01-04
申请号：US18254058
申请日：2021-11-24
Applicant: SOCIETE DES PRODUITS NESTLE S.A.
Inventor： SHAILLAY KUMAR DOGRA
Abstract: The present invention relates to systems and methods for predicting individual microbiome status and for providing personalized recommendations to maintain or improve the microbiome status. In several embodiments of the invention, the individual microbiome features are clustered based on their responses to a questionnaire. In several embodiments, the methods are implemented by a computer system. In several embodiments of the invention, personalized recommendations and dietary advice are given to the individual to maintain or improve said individual's microbiome status.
